Nav: Home

Researchers at IDIBELL-ICO describe a new resistance mechanism

July 02, 2019

Researchers at IDIBELL-ICO describe a new resistance mechanism to therapies that prevent the formation of blood vessels
  • The mechanism does not activate the reduction of oxygen in the cells of the tumor, contrary to what common drugs, called anti-angiogenic, usually cause.
  • In response to treatment, the immune cells of the tumor act as elements that make the tumor malignant.
Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and the ProCure Program of the Catalan Institute of Oncology (ICO) published today at Cancer Research a study describing a new mechanism in cancer that turns cells into malignant cells and contradicts what had been published so far about drug resistance that prevent the formation of blood vessels (anti-angiogenics). The research has been led by Dr. Oriol Casanovas, from the group of Tumor Angiogenesis of the IDIBELL, and the Dra. Iratxe Zuazo has participated as one of the first authors.

In the search for alternative factors to fight cancer, antibody development as a therapeutic route is one of them. Antibodies can have an anti-tumor effect, preventing tumors from developing properly. In this study, scientists observed that one of these antibodies led to similar effects to those known for traditional antiangiogenic medications. However, the initial response to treatment culminated in the appearance of long-term resistance and malignancy through a mechanism unknown to date.

"In the formation of blood vessels (angiogenesis) it had been described that the conditions of low oxygen concentration (hypoxia) in the tumor were the cause of malignization of the tumor cells that became more aggressive and migrated" says Dr. Iratxe Zuazo, "but our samples did not present hypoxia conditions and we still had this effect".

The antibody of the study had the target Semaphorin 4D (Sema4D). Semaphorins are a large and diverse family of proteins from outside the cells, involved in cell signaling, and are essential for the development and maintenance of many organs and tissues. Some of them have implications for angiogenesis and cancer progression. Its name comes from the Greek semaphero, that means "bearer of signals".

Sema4D is a protein that is expressed predominantly in the membrane of solid tumors, in cancers such as breast, prostate and colon cancer. This protein is also found in tumor-associated macrophages (TAMs), which are immune cells that play an important role in tumor invasion, tumor formation and in metastasis. The 4D Semaphorin is also related to the formation of blood vessels.

Faced with this new situation, the researchers looked for which could be the differential factor from what was known to date, and they realized that there was a large presence of macrophages. They saw that, in the presence of the anti-Sema4D antibody, the macrophages secreted a molecule named SDF1, which causes the tumor cells to migrate more: they present more motility and more invasion.

These tests were done in transgenic mice models and what was observed was an increased survival of animals in the short term. In the long term, however, an unwanted effect (metastasis) was generated, significantly worsening the condition of the mice.

"Now that we know the new mechanism, we can begin to look for a way to inhibit it - for example, avoiding secretion of SDF1- and, in this way, to give an alternative to only have the positive effects of the antibody" explains Dr. Oriol Casanovas. He adds that "depending on each case, treatments could be carried out simultaneously with two drugs at the same time".

"What we propose is that the immune system is also taken into account when doing some therapies, because now we know that there may be the possibility of activating it with some drugs", concludes Dr. Iratxe Zuazo.
-end-


IDIBELL-Bellvitge Biomedical Research Institute

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...